Evidence map›Paper›PMID 39009885›Full record

ArticleEMBO molecular medicine2024

In vitro and in vivo inhibition of the host TRPC4 channel attenuates Zika virus infection.

Xingjuan Chen, Yunzheng Yan, Zhiqiang Liu, Shaokang Yang, Wei Li, Zhuang Wang, Mengyuan Wang, Juan Guo, Zhenyang Li, Weiyan Zhu and 13 more

Abstract read
In one paragraph

Article in EMBO molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Transient receptor potential channels inChannels (Austin, Tex.) · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Xingjuan Chen *Institute of Medical Research, Northwestern Polytechnical University, 710072, Xi'an, Shanxi, China.ORCID http://orcid.org/0000-0002-7380-8399
Yunzheng Yan *National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, China.
Zhiqiang Liu *Beijing Institute of Basic Medical Sciences, Beijing, China.
Shaokang Yang *National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, China.
Wei LiNational Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, China.
Zhuang WangInstitute of Medical Research, Northwestern Polytechnical University, 710072, Xi'an, Shanxi, China.
Mengyuan WangInstitute of Medical Research, Northwestern Polytechnical University, 710072, Xi'an, Shanxi, China.
Juan GuoInstitute of Medical Research, Northwestern Polytechnical University, 710072, Xi'an, Shanxi, China.
Zhenyang LiNational Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, China.
Weiyan ZhuNational Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, China.
Jingjing YangNational Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, China.
Jiye YinNational Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, China.
Qingsong DaiNational Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, China.
Yuexiang LiNational Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, China.
Cui WangBeijing Institute of Basic Medical Sciences, Beijing, China.
Lei ZhaoNational Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, China.
Xiaotong YangNational Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, China.
Xiaojia GuoNational Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, China.
Ling LengState Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID http://orcid.org/0000-0002-6519-012X
Jiaxi XuDepartment of Physiology and Pathophysiology, Xi'an Jiaotong University Health Science Center, 710061, Xi'an, Shanxi, China.ORCID http://orcid.org/0000-0002-0694-813X
Alexander G ObukhovThe Department of Anatomy, Cell Biology & Physiology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA. aobukhov@iu.edu.ORCID http://orcid.org/0000-0002-3862-6004
Ruiyuan CaoNational Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, China. caoruiyuan@bmi.ac.cn.ORCID http://orcid.org/0000-0002-5459-4495
Wu ZhongNational Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, China. zhongwu@bmi.ac.cn.ORCID http://orcid.org/0000-0002-0536-620X

Funding

The role of cell-specific TLR-4 signaling in oxaliplatin-induced peripheral neuropathyR01NS102415 · NINDS · INDIANA UNIVERSITY INDIANAPOLIS · PI WHITE, FLETCHER A · 2018 to 2022
$2.2M
Foundation for the National Institutes of Health (FNIH) NS102415MOST | National Natural Science Foundation of China (NSFC) 81773631MOST | National Natural Science Foundation of China (NSFC) 81900402NINDS NIH HHS R01 NS102415
6 · The paper itself

Abstract

Zika virus (ZIKV) infection may lead to severe neurological consequences, including seizures, and early infancy death. However, the involved mechanisms are still largely unknown. TRPC channels play an important role in regulating nervous system excitability and are implicated in seizure development. We investigated whether TRPCs might be involved in the pathogenesis of ZIKV infection. We found that ZIKV infection increases TRPC4 expression in host cells via the interaction between the ZIKV-NS3 protein and CaMKII, enhancing TRPC4-mediated calcium influx. Pharmacological inhibition of CaMKII decreased both pCREB and TRPC4 protein levels, whereas the suppression of either TRPC4 or CaMKII improved the survival rate of ZIKV-infected cells and reduced viral protein production, likely by impeding the replication phase of the viral life cycle. TRPC4 or CaMKII inhibitors also reduced seizures and increased the survival of ZIKV-infected neonatal mice and blocked the spread of ZIKV in brain organoids derived from human-induced pluripotent stem cells. These findings suggest that targeting CaMKII or TRPC4 may offer a promising approach for developing novel anti-ZIKV therapies, capable of preventing ZIKV-associated seizures and death.

Indexed as

Calcium-Calmodulin-Dependent Protein Kinase Type 2TRPC Cation ChannelsZika VirusZika Virus InfectionAnimalsDEAD-box RNA HelicasesHEK293 CellsHumansMiceNucleoside-TriphosphataseSeizuresSerine EndopeptidasesViral ProteasesViral ProteinsVirus ReplicationCalcium-Calmodulin-Dependent Protein Kinase Type 2DEAD-box RNA HelicasesNS3 protein, Zika virusNucleoside-TriphosphataseSerine EndopeptidasesTRPC4 ion channelTRPC Cation ChannelsViral ProteasesViral ProteinsAntiviral TargetCalciumEpilepsyTRPC4 ChannelZika Virus

Identifiers

PMID39009885
PMCPMC11319825

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.